Vaxcyte Stock Hits New 52-Week High - Here’s Why
Key takeaways
- Vaxcyte’s OPUS‑1 success could fast‑track a 31‑valent vaccine and lift its stock sharply.
- VAX‑31 met all 28 shared serotype noninferiority criteria
- VAX‑31 superior for 3 unique serotypes
- 56.91% share increase to $88.62
What happened
Vaxcyte Inc. (NASDAQ: PCVX) announced that its Phase 3 OPUS‑1 trial of the 31‑valent pneumococcal vaccine VAX‑31 met all prespecified co‑primary immunogenicity endpoints in adults 50 and older, showing noninferiority to both Pfizer’s Prevnar 20 and Merck’s Capvaxive across 28 shared serotypes and superiority for three unique serotypes.
Why it matters
The results give Vaxcyte a strong scientific foundation for a U.S. Biologics License Application, potentially positioning its vaccine as a next‑generation pneumococcal product that could capture market share from existing 20‑ and 21‑valent vaccines.
Short-term and longer-term
Short-term. In the next 24–48 hours, PCVX could see further volatility as analysts digest the trial data and assess the likelihood of a timely FDA submission.
Longer-term. Over the next 6–12 months, the company’s ability to secure a license for VAX‑31 will be critical to its long‑term valuation.